Clinical and clonal characteristics of monoclonal immunoglobulin M‐associated type I cryoglobulinaemia
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19112 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Jahanzaib Khwaja und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, University College London Hospital, London, UK. Hauptthemen laut MEDLINE: Cryoglobulinemia, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Lymphoma, B-Cell. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Monoclonal immunoglobulin M‐associated type I cryoglobulinaemia is poorly characterised. We screened 534 patients with monoclonal IgM disorders over a 9‐year period and identified 134 patients with IgM type I cryoglobulins. Of these, 76% had Waldenström macroglobulinaemia (WM), 5% had other non‐Hodgkin lymphoma (NHL) and 19% had IgM monoclonal gammopathy of undetermined significance (MGUS). Clinically relevant IgM‐associated disorders (including cold agglutinin disease [CAD], anti‐MAG antibodies, amyloidosis and Schnitzler syndrome) coexisted in 31%, more frequently in MGUS versus WM/NHL (72% vs. 22%/29%, p < 0.001). The majority of those with cryoglobulins and coexistent CAD/syndrome had the molecular characteristics of a CAD clone (wild‐type MYD88 in 80%). A half of all patients had active manifestations at cryoglobulin detection: vasomotor (22%), cutaneous (16%), peripheral neuropathy (22%) and hyperviscosity (9%). 16/134 required treatment for cryoglobulin‐related symptoms alone at a median of 38 days (range: 6–239) from cryoglobulin detection. At a median follow‐up of 3 years (range: 0–10), 3‐year cryoglobulinaemia‐treatment‐free survival was 77% (95% CI: 68%–84%). Age was the only predictor of overall survival. Predictors of cryoglobulinaemia‐related treatment/death were hyperviscosity (HR: 73.01; 95% CI: 15.62–341.36, p < 0.0001) and cutaneous involvement (HR: 2.95; 95% CI: 1.13–7.71, p = 0.028). Type I IgM cryoglobulinaemia is more prevalent than previously described in IgM gammopathy and should be actively sought.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, University College London Hospital, London, UK.
- Department of Haematology, Amsterdam UMC, Amsterdam, The Netherlands.
- Health Services Laboratories, London, UK.
- Department of Internal Medicine, Clinical Immunology/Allergy and Nephrology Amsterdam UMC, Amsterdam, The Netherlands.
ORCID-Profile: Jahanzaib Khwaja
Zitieren
APA
Khwaja, J., Vos, J. M. I., Pluimers, T. E., Japzon, N., Patel, A., Salter, S., Kwakernaak, A. J., Gupta, R., Rismani, A., Kyriakou, C., Wechalekar, A. D., & D'Sa, S. (2024). Clinical and clonal characteristics of monoclonal immunoglobulin M‐associated type I cryoglobulinaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.19112
Vancouver
Khwaja J, Vos JMI, Pluimers TE, Japzon N, Patel A, Salter S, et al. Clinical and clonal characteristics of monoclonal immunoglobulin M‐associated type I cryoglobulinaemia. British Journal of Haematology. 2024. doi:10.1111/bjh.19112
BibTeX
@article{Khwaja2024,
author = {Khwaja, Jahanzaib and Vos, Josephine M I and Pluimers, Tessa E and Japzon, Nicole and Patel, Aisha and Salter, Simon and Kwakernaak, Arjan J and Gupta, Rajeev and Rismani, Ali and Kyriakou, Charalampia and Wechalekar, Ashutosh D and D'Sa, Shirley},
title = {Clinical and clonal characteristics of monoclonal immunoglobulin M‐associated type I cryoglobulinaemia},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19112}
}
EUVIMED